Date post: | 15-Jan-2016 |
Category: |
Documents |
View: | 216 times |
Download: | 0 times |
ATAGC TSI
Molecular associations of IFTA
Michael MengelAlberta Transplant Applied Genomics Centre
University of Alberta, Edmonton Canada
ATAGC TSI
Interstitial fibrosis and tubular atrophy (IFTA) in renal allografts
ATAGC TSI
IFTA with inflammation
ATAGC TSI
Issues with doing analysis for the causes / associates of IFTA
• Most studies group comparisons “sick vs. well”, i.e. biopsies with moderate to severe IFTA are compared to normal biopsies without IFTA: starting with the extreme phenotypes
• Cave! The first group generally has a lot of other pathologies while the others are really normal, thus it’s difficult to see whether the findings are related to IFTA or to a co-existing finding, e.g. interstitial inflammation or time post transplant
ATAGC TSI
Example 1 of a “sick vs. well” studyTitle: “Molecular pathways involved in loss of kidney graft
function with tubular atrophy and interstitial fibrosis.”
Mol Med. 2008 May-Jun;14(5-6):276-85.
ATAGC TSI
Scoring inflammation in renal allograft biopsies
60% IFTA compartment40% non-scarred compartment
100% Cortex
relative scoring
according to current Banff
rules
25% = Banff i-score 1 “67% i-IFTA”
5% 3% 3% 5%
absolute scoring40% i-IFTA10% i-Banff
nodular
perivascular
subc
ap
sula
r
ATAGC TSI
Material and Methods
• 129 biopsies for cause classified according to Banff ‘97
• Semi-quantitative assessment as absolute percentages of:– i-Banff = inflammation in non scarred cortex– i-IFTA = inflammation in IFTA– nodular– perivascular– IFTA
• Correlation of extent of histological lesions with gene expression data from microarrays and allograft survival
ATAGC TSI
0
10
20
30
40
50
60
70
80
90
100
1 6 11 16 21 26 31 36 41 46 51 56 61 66 71 76 81 86 91 96 101 106 111 116 121 126
% c
ort
ex in
volv
ed
fibrosis/atrophy
i-Banff
i-IFTA
Infiltrates in biopsies for cause are time dependent
3 months
8 months
27 months
79 months
246 months
129 biopsies ordered by time post TX
Mengel et al. Am J Transplant. 2009 Jan;9(1):169-78.
ATAGC TSI
Infiltrates and time in BFC
0
5
10
15
20
25
30
<6 months post TX, n=42 >6 months post TX, n=87
me
an
% c
ort
ex
inv
olv
ed
nodular
perivascular
i-Banff
i-IFTA
IFTA
p<0.0001
p<0.0001
ATAGC TSI
Inflammation in fibrosis/atrophy is associated with worse allograft survival
A
Inclusion criteria: IFTA >5%, i-Banff <25%
graft survival n
≥50% of fibrosis/atrophy show infiltrates 69.6% 46
<50% of fibrosis/atrophy show infiltrates 93.5% 31
censored 77+
uninflamed IFTA
inflamed IFTA
p=0.02
B
biopsies with graft survival n
i-Banff >25%, i-IFTA <25% 69.2% 13 i-IFTA >25%, i-Banff <25% 60.0% 20 both <25% 88.7% 71 censored 104 +
i-Banff
i-IFTA
i <25%
p<0.05
ATAGC TSI
Gene sets*# i-Banff
t-score i-IFTA IFTA nodular
perivascular
T-cell associated (CATs) 0.534 0.484 0.284 0.246 0.298 ns
γ-Interferon dependent (GRITs) 0.532 0.441 0.258 0.211 0.241 ns
Kidney parenchyma associated (KTs) -0.296 -0.303 -0.199
-0.156 ns ns
Injury and repair associated (IRITs) 0.379 0.355 0.246 0.206 ns ns
Immunoglobulin associated (IGTs) 0.174 ns 0.434 0.398 0.336 ns
B-cell associated (BATs) 0.281 0.279 0.423 0.387 0.355 ns
# given is the highest r-value revealed for one PBT of each particular biological process*Spearman correlation, p<0.001
Table 1: Correlations between Infiltrate types and Pathogenesis Based Transcript sets (PBTs)
ATAGC TSI
Correlations* between individual genes and histological lesions
0
10
20
30
40
50
60
70
80
90
100
i-Banff Banff t-score i-IFTA fibrosis/atrophy nodular
% c
ontr
ibut
ion
not otherwise annotated
Endothelial activation
B-cell / Ig associated
Injury and repair associated
Kidney parenchyma associated
Macrophage associated
Interferon-γ dependent
T-cell associated
484 probesets 249 probesets 34 probesets172 probesets202 probesets
*r>0.4, p<0.001: no correlations between any genes and perivascular infiltrates at this cut-off
T-c
ell
T-c
ell
T-c
ell
γ-IF
N γ-IF
N
B-c
ell
B-c
ell
B-c
ell
Ma
c
Ma
c
InjuryInjury
Injury
Injury
ATAGC TSI
Figure 3: Overlap in gene expression between infiltrate types
i-Banff t-score
244
240116 cytotoxic T cell associated
54 not annotated39 γ-interferon dependent
14 Injury and Repair induced17 macrophage associated
9
i-IFTA IFTA
70
13284 not annotated
26 B cell associated15 Injury and Repair induced3 cytotoxic T cell associated
3 Kidney parenchymal1 Endothelial activation 40
ATAGC TSI
Genes (top 25) correlating with fibrosis/atrophy and i-IFTA
Affymetrix ID Gene symbol
Gene name Correlation* r-value
205624_at CPA3 mast cell carboxypeptidase A3 0.619207134_x_at TPSB2 mast cell tryptase beta 2 0.566204719_at ABCA8 ABC transporters - ATP-binding cassette, sub-family A (ABC1), member 8 0.564205683_x_at TPSAB1 mast cell tryptase alpha/beta 1 0.555205044_at GABRP gamma-aminobutyric acid (GABA) A receptor 0.554211734_s_at FCER1A receptor for Fc fragment of IgE, high affinity I, expressed predominantely on mast cells 0.547209173_at AGR2 anterior gradient homolog 2 0.523229461_x_at NEGR1 neuronal growth regulator 1 0.509213974_at ADAMTSL3 ADAMTS-like 3 0.503221933_at NLGN4X neuroligin 4 0.499228310_at ENAH cytoskeleton regulatory protein hMena 0.497202508_s_at SNAP25 synaptosomal-associated protein 0.497226435_at PAPLN papilin 0.486228241_at BCMP11 AGR3 = anterior gradient homolog 3 0.485219552_at SVEP1 sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 0.484227088_at PDE5A phosphodiesterase 5A 0.479219778_at ZFPM2 zinc finger protein, multitype 2 0.474207496_at MS4A2 Fc fragment of IgE, high affinity I, receptor for; beta polypeptide 0.47202992_at C7 Complement compnent 7 0.4681558714_at ROBO1 roundabout, axon guidance receptor, homolog 1 0.467219867_at CHODL chondrolectin 0.466206336_at CXCL6 chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) 0.466210258_at RGS13 regulator of G-protein signaling 13 0.462201489_at PPIF peptidylprolyl isomerase F (cyclophilin F, CYP3; Cyp-D) -0.47208321_s_at CABP1 calcium binding protein 1 -0.49
*Spearman correlation with extent of fibrosis/atrophy or i-IFTA, p<0.001
ATAGC TSI
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
% T cells (CD3+) % Macropahges(CD68+)
% B cells (CD20+) % plasma cells(CD138+)
% IgG4 plasma cells(IgG4+)
% mast cells(tryptase+)
%
i-non-IFTA
i-IFTA
Confirmation by immunohistochemistry
p 0.006
p 0.02
p 0.006
p 0.05
p 0.0004
i-Banff
i-IFTA
ATAGC TSI
Mast cell associate transcript set (MACAT)
4 mast cell associated transcripts– CPA3 (Carboxypeptidase 3)– TPSB2 (Tryptase beta 2) – TPSAB1 ( Tryptase alpha-beta 1)– FCER1A (Fc fragment of IgE, high affinity I, receptor)
ATAGC TSI
0
0.5
1
1.5
2
2.5
i-non-IFTA<25%, n=109
i-non-IFTA>25%, n=20
i-IFTA <25%,n=102
i-IFTA >25%,n=27
IFTA <25%,n=87
IFTA >25%,n=42
Mas
t cel
l PBT
sco
re
p<0.0001
i-Banff<25%, n=109
i-Banff>25%, n=20
Mast cell associated transcripts are a molecular correlate of IFTA
Mast cell transcripts correlate with
time post TX: r=0.55, p <0.01
i-IFTA: r=0.63, p <0.01
IFTA: r=0.61, p <0.01
delta GFR: r= -0.35, p <0.0001
ATAGC TSI
In biopsies with IFTA increased expression of Mast cell associated transcript is associated with worse allograft survival
Inclusion criteria: at least IFTA grade I
graft survival n
high* MACAT score 71.2% 29
low* MACATscore 96.6% 59
censored 88
*low = lowest tertile of MACAT score of the included 88 biopsies*high = intermediate and highest tertile of MACAT score of the included 88 biopsies
+
high mast cell scoresp=0.01
low mast cell scores
ATAGC TSI
Summary IFTA and infiltrates
• There are two inflammatory compartments in renal allografts:
– i-Banff (non-scarred): • time-independent, T-cell, γ-interferon, macrophage associated,
prognostic relevant
– i-IFTA (scarred): • time-dependent, T-cell, γ-interferon, macrophage + B-cell, mast
cell associated, prognostic relevant
ATAGC TSI
Relationship between IFTA and function in native kidneys
ATAGC TSI
Relationship between IFTA and function in renal allografts (biopsies for cause)
Kasiske et al. Kidney Int. 1991;40:514-524
ATAGC TSI
IMATs (Mactrophage activation)
IGTs (Plasma cell infiltration)
CISTs (severe injury)
GSTs (severe injury)
BATs (B cell infiltration)
GRIT1 (Ifng effects)
GRIT2 (Ifng effects)
KT1 (Parenchymal transcripts)
IRITD5 (Injury)
IRITD3 (Injury)
IRITD1 (Injury)
CMATs (Macrophage infiltration)
CATs (T cell infiltration)
An
no
tati
on
of
pro
bes
ets
(% o
f to
tal o
f co
rrel
atin
g p
rob
eset
s)
0
5
10
15
20
25
30
35
40
45
Negative Correlation Positive Correlation
n = 144
n = 224
GFR transcript set
Molecular correlates of eGFR at the time of biopsy
Bunnang and Einecke et al. J Am Soc Nephrol. 2009 (5):1149-60
GFRT Negative
GFRT Positive
Histologic lesions (Banff scores)*
g 0.09 -0.10
cg 0.03 0.03
i 0.33** -0.32**
ci 0.29** -0.20**
t 0.16 -0.19*
ct 0.29** -0.20*
v -0.02 -0.02
cv -0.09 0.17*
ah -0.17* 0.21*
mm 0.17 0.05
PTC 0.07 -0.08
Renal function
eGFR at Biopsy -0.54** 0.50**
Functional deterioration from baseline (delta eGFR) -0.28** -0.30**
ATAGC TSI
Significant overlap between injury / repair / and IFTA associated transcripts
Am J Transplant. 2007 Nov;7(11):2483-95.
ATAGC TSI
Numerous “fibrosis genes” are associated with injury and repair
Early IRITs Intermediate IRITs Late IRITs
Category % of genes in the list % of genes in the list % of genes in the list
Response to stress (832) 4.8 7.4 9.1
Morphogenesis (n=951) 5.2 8.0 6.9
Organ development (991) 3.8 8.9 8.7
Embryonic kidney (n=904) 7.1 10.6 6.1
Ureteric bud vs mesenchyme (n=933) 6.7 12.6 7.4
Embryonic mesenchyme (n=951) 2.9 9.7 11.3
Mesenchyme vs ureteric bud (n=751) 4.8 8.0 19.9
Cell cycle and cell proliferation (n=1008) 2.4 8.3 10.4
Tgfb1/fibrogenesis (n=48) 1.9 3.2 6.1
Collagen (n=36) 0.5 1.1 4.3
ECM (n=431) 1.9 4.0 12.1
ATAGC TSI
Molecular changes in protocol biopsiesBackground and Hypothesis
early protocol biopsy
subclinical pathology = harbinger of more severe, clinical overt, irreversible pathology
therapeutic intervention prevention of irreversible chronic allograft damage
assessment of the
subclinical molecular phenotype of an allograft to further corroborate this hypothesis
ATAGC TSI
No molecular evidence for EMT in the onset of IFTA in early protocol biopsies
J Am Soc Nephrol. 2008 Aug;19(8):1571-83.
ATAGC TSI
Molecular associates of subclinical IFTA at 12-months in clinically uncomplicated living donor kidney transplants
Transplantation. 2007 Jun 15;83(11):1466-76
ATAGC TSI
PBT-annotation of top 100 transcripts correlating* in 6-week protocol biopsies with future onset of
IFTA in 6-month protocol biopsies
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
correlated with onset of IFTA at 6-months post TX
correlated with delta clearance 6-weeks to 12-months
correlated with prevalence of acute rejection between 6-weeks and 12-months
after transplantation
Endothel associated transcripts
TGF-β related transcripts
kidney parenchymal transcripts
injury induced transcripts
interferon-γ inducible transcripts
macrophage associated transcripts
B cell associated transcripts
NK cell associated transcripts
T cell associated transcripts
*Spearman correlation, p<0.001
ATAGC TSI
PBT-annotation of top 100 transcripts correlating* with future end points in PB
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
correlated with onset of IFTA at 6-months post TX
correlated with delta clearance 6-weeks to 12-months
correlated with prevalence of acute rejection between 6-weeks and 12-months
after transplantation
Endothel associated transcripts
TGF-β related transcripts
kidney parenchymal transcripts
injury induced transcripts
interferon-γ inducible transcripts
macrophage associated transcripts
B cell associated transcripts
NK cell associated transcripts
T cell associated transcripts
*Spearman correlation, p<0.001
ATAGC TSI
Conclusions: Molecules and IFTA
• IFTA by histology is associated with inflammation and injury / repair molecules = sign of active/progressive IFTA or attempt to recovery?
• Conclusion about cause for IFTA is yet not possible• Some molecular correlates (e.g. mast cells) might
be used as a measurement for IFTA• More detailed resolution of the overall molecular
disturbance might provide potential therapeutic targets for a non-cause specific anti IFTA treatment
ATAGC TSI
Outlook
• Test reproducibility for IF, TA, i-Banff, i-IFTA, and total i-score: – if feasible, reporting of the different
inflammatory and morphological compartments might allow to design new clinical trials
– i-Banff and i-IFTA might be amenable to different therapies